NCT04712721 2025-10-10
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Novartis
Phase EARLY_PHASE1 Terminated
Novartis
Blue Earth Therapeutics Ltd
Novartis
Five Prime Therapeutics, Inc.
Miltenyi Biomedicine GmbH
SpectronRX
Amgen
Samus Therapeutics, Inc.
Oncolytics Biotech
Presage Biosciences
Hoffmann-La Roche
Peregrine Pharmaceuticals
MelCure SA